Hospira, Inc. has entered into an agreement to acquire Mayne Pharma for $2 billion. The acquisition adds generic capabilities and broadens Hopsira’s global reach. “This combination will create the leading generic injectable pharmaceuticals company in the world—delivering unparalleled value to the global healthcare system as well as our respective shareholders and employees,” said Christopher B. Begley, chief executive officer, Hospira. “The Mayne acquisition more th...